# Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

> **NCT03327662** · PHASE3 · TERMINATED · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 12 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **OTHER:** Active CTC Assessment

## Key facts

- **NCT ID:** NCT03327662
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-11
- **Primary completion:** 2019-11
- **Final completion:** 2020-04
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Underrecruitment
- **Last updated:** 2021-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03327662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03327662, "Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03327662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*